As part of DAY 1's programme at the BIO Africa Convention 2020 (24th August), there will be an integral conversation featuring highly-accomplished scientists.
About Professor Quarraisha Abdool Karim
Professor Quarraisha Abdool Karim, PhD, is a distinguished, South African specialist in infectious diseases epidemiology. She is the Associate Scientific Director of CAPRISA, Professor of Epidemiology at the Mailman School of Public Health, Columbia University and Adjunct Professor in Public Health at the Nelson R Mandela School of Medicine, University of KwaZulu-Natal, South Africa. Prof. Abdool Karim is a globally celebrated, pioneer of excellence when it comes to AIDS research.
She has made vital contributions in understanding the evolving HIV epidemic in South Africa - factors influencing acquisition of HIV infection in adolescent girls; and sustainable strategies to introduce ART in resource-constrained settings. Her most important scientific contribution to HIV prevention is the CAPRISA 004 tenofovir gel trial, which demonstrated the effectiveness of coitally-applied tenofovir gel in preventing HIV and HSV-2 acquisition in women.
Her illustrious professional capacity includes career highlights such as her role as the UNAIDS Special Ambassador for Adolescents and HIV, as well as her position as Co-Chair of the UNAIDS Advisory Group. She is also the Vice President for the African Academy of Science, Southern Africa, and Foreign Associate Member of the Institute of Medicine (IoM) of the National Academies. Most recently, Professor Abdool Karim was bestowed with the prestigious Christophe Mérieux Prize for 2020.
More about her research:
Research Papers: Lead researcher/ Author COVID-19 affects HIV and tuberculosis care. 2020. Science: 366-368. DOI: 10.1126/science.abd1072. Putting women in the centre of the global HIV response is key to achieving epidemic control! 2020. J Int AIDS Soc. 23(3): e25473. doi: 10.1002/jia2.25473.
This year's event will take place virtually, and access to the convention will be free of charge. Registration is now open.
Comments